Skip to main content
. Author manuscript; available in PMC: 2016 Jun 7.
Published in final edited form as: Gene Ther. 2013 Nov 28;21(2):139–147. doi: 10.1038/gt.2013.66

Figure 5.

Figure 5

Comparison of defect healing under the effect of GCV administration for 2 weeks from days 14 to 28 in group IA (GCV treated) vs group IB (control PBS treated). A total of 2 × 106 MBMCs transduced with LV-BMP-2 were placed in the defects. GCV treatment did not cause any significant delay in bone healing, as all the defects in both groups were healed at 4 weeks.